Journal article
Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature
Osteoporosis international, Vol.29(9), pp.1987-2009
09/01/2018
DOI: 10.1007/s00198-018-4574-x
PMID: 29923062
Abstract
Hyperphosphatemic familial tumoral calcinosis (HFTC), secondary to fibroblast growth factor 23 (FGF23) gene mutation, is a rare genetic disorder characterized by recurrent calcified masses. We describe young Lebanese cousins presenting with HFTC, based on a retrospective chart review and a prospective case study. In addition, we present a comprehensive review on the topic, based on a literature search conducted in PubMed and Google Scholar, in 2014 and updated in December 2017. While the patients had the same previously reported FGF23 gene mutation (homozygous c.G367T variant in exon 3 leading to a missense mutation), they presented with variable severity and age of disease onset (at 4 years in patient 1 and at 23 years in patient 2). A review of the literature revealed several potential patho-physiologic pathways of HFTC clinical manifestations, some of which may be independent of hyperphosphatemia. Most available treatment options aim at reducing serum phosphate level, by stimulating renal excretion or by inhibiting intestinal absorption. HFTC is a challenging disease. While the available medical treatment has a limited and inconsistent effect on disease symptomatology, surgical resection of calcified masses remains the last resort. Research is needed to determine the safety and efficacy of FGF23 replacement or molecular therapy, targeting the specific genetic aberration. Hyperphosphatemic familial tumoral calcinosis is a rare genetic disorder characterized by recurrent calcified masses, in addition to other visceral, skeletal, and vascular manifestations. It remains a very challenging disease.
Details
- Title: Subtitle
- Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature
- Creators
- M. Chakhtoura - American University of Beirut Medical CenterM. S. Ramnitz - National Institutes of HealthN. Khoury - American University of Beirut Medical CenterG. Nemer - American University of Beirut Medical CenterN. Shabb - American University of Beirut Medical CenterA. Abchee - American University of Beirut Medical CenterA. Berberi - American University of Beirut Medical CenterM. Hourani - American University of Beirut Medical CenterM. Collins - National Institute of Dental and Craniofacial ResearchS. Ichikawa - Indiana University – Purdue University IndianapolisG. El Hajj Fuleihan - Amer Univ Beirut, Calcium Metab & Osteoporosis Program, WHO Collaborating Ctr Metab Bone Disorders, Med Ctr, Beirut, Lebanon
- Resource Type
- Journal article
- Publication Details
- Osteoporosis international, Vol.29(9), pp.1987-2009
- Publisher
- Springer Nature
- DOI
- 10.1007/s00198-018-4574-x
- PMID
- 29923062
- ISSN
- 0937-941X
- eISSN
- 1433-2965
- Number of pages
- 23
- Grant note
- Medical Resource Plan at the American University of Beirut Fogarty International Center; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC) D43TW009118 / Office of Dietary Supplements of the National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Language
- English
- Date published
- 09/01/2018
- Academic Unit
- Radiology
- Record Identifier
- 9984697733402771
Metrics
5 Record Views